HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Polish experience in Peptide receptor radionuclide therapy.

AbstractPATIENTS AND METHODS:
During the period from April 2004 to December 2010, 358 patients underwent peptide receptor radionuclide therapy (PRRT) ((90)Y-DOTATATE, (177)Lu-DOTATATE, and (90)Y/(177)Lu-DOTATATE) in Poland.
RESULTS:
The majority of patients underwent (90)Y-DOTATATE therapy (n = 177) with progression-free survival (PFS)/time to progression (TTP) of 17-44 months and overall survival (OS) of 22-34.2 months. Twelve-month follow-up revealed stable disease (SD) in 46-60%, disease regression (RD) in 16-35%, disease progression (PD) in 7-17%, and complete remission (CR) in 3% of patients. In patients treated with (90)Y/(177)Lu-DOTATATE (n = 44), PFS/TTP was 24.2-28.3 months and OS was 49.8-52.8 months. Twelve-month follow-up showed SD in 62-70%, RD in 15-20%, and PD in 10-12% of patients. The treatment was well tolerated. No severe adverse events occurred. Grade 3 toxicity [in leucocytes (WBC) and thrombocytes (PLT)] was seen in 6-20% of patients treated with (90)Y-DOTATATE. In that group, renal toxicity grade 3 was seen in 5-12% and grade 4 in 3-8%. In patients treated with tandem therapy with (90)Y/(177)Lu-DOTATATE or (177)Lu-DOTATATE alone, hematological and renal toxicity grade 3 or 4 was not observed.
CONCLUSIONS:
The results indicate that PRRT with the procedures and isotopes used is an effective and safe therapy option for patients with metastatic or inoperable neuroendocrine tumors (NETs). Our results suggest that tandem therapy with (90)Y/(177)Lu-DOTATATE provides longer overall survival than single-isotope treatment. Hematological toxicity was rare in all treated patients. Renal toxicity grade 3 and 4 was observed only in the group treated with (90)Y-DOTATATE.
AuthorsJolanta Kunikowska, Leszek Królicki, Anna Sowa-Staszczak, Alicja Hubalewska-Dydejczyk, Dariusz Pawlak, Renata Mikolajczak, Daria Handkiewicz-Junak, Norbert Szaluś, Grzegorz Kamiński, Jaroslaw Cwikla, Maciej Jakuciński, Anna Lukiewicz, Aldona Kowalska, Pawel Gut
JournalRecent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer (Recent Results Cancer Res) Vol. 194 Pg. 467-78 ( 2013) ISSN: 0080-0015 [Print] Germany
PMID22918776 (Publication Type: Journal Article)
Chemical References
  • Organometallic Compounds
  • Radioisotopes
  • Radiopharmaceuticals
  • Receptors, Somatostatin
  • Yttrium Radioisotopes
  • Lutetium
  • lutetium Lu 177 dotatate
  • Octreotide
Topics
  • Humans
  • Lutetium (therapeutic use)
  • Neuroendocrine Tumors (chemistry, mortality, radiotherapy)
  • Octreotide (analogs & derivatives, therapeutic use)
  • Organometallic Compounds (therapeutic use)
  • Radioisotopes (therapeutic use)
  • Radiopharmaceuticals (adverse effects, therapeutic use)
  • Receptors, Somatostatin (analysis)
  • Yttrium Radioisotopes (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: